// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Right Atrial Function and Fibrosis in Relation to Successful Atrial Fibrillation Ablation

Luuk H Hopman - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Arrhythmia

N/A

Association of Obesity With Incident Atrial Fibrillation in Korea and the United Kingdom

Sung Hwa Choi - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Arrhythmia

N/A

Using Pre-Operative Cardiac Computed Tomography and Echocardiography to Predict New-Onset Atrial Fibrillation Following TAVR

Mark S Brahier - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Arrhythmia

N/A

Pacing-Induced Cardiomyopathy A Systematic Review and Meta-Analysis of Definition, Incidence, Risk Factors and Management

Vincenzo Somma - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Pacing induced cardiomyopathy

N/A

Real-World Healthcare Resource Utilization Outcomes With Dronedarone versus Sotalol Following Ablation in Adults With Atrial Fibrillation

Emily P Zeitler - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Arrhythmia

Dronedarone

APOE ε4 Carriage Associates With Improved Myocardial Performance in Older Age

Constantin-Cristian Topriceanu - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Hypertension

N/A

Using a Trial Modelling Framework to Emulate a Target Trial Evaluating Revascularisation Strategies in Patients With Heart Failure

Suraj Pathak - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

N/A

Is Atrial Fibrillation in HFpEF a Distinct Endotype? Insights From Multiparametric MRI and Circulating Fibroinflammatory Markers

Abhishek Dattani - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Arrhythmia

N/A

Disparities in Cardiovascular Death Proportions Based on Age-Standardized Gross Domestic Product Classification of Countries Global Burden of Disease 2019

Anoop Titus - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

An Ambulatory Syncope Service is a Safe Pathway to Reduce Hospital Admissions

Brian X Wang - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Syncope

N/A

The Biochemical and Physiological Pathways From Obesity to Cardiovascular Disease A Prospective Cohort Study of 404332 UK Biobank Participants

Ziyi Zhou - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Obesity

N/A

Nationwide Trends in Subsequent Myocardial Infarction Hospitalizations and Mortality in Elderly Patients With Prior Myocardial Infarction and Associated Racial/Socioeconomic Disparities A National Inpatient Sample Analysis

Akhil Jain - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Myocardial infarction

N/A

Patients Admitted With Type 2 Acute Myocardial Infarction Without Standard Modifiable Risk Factors Have Worse Outcomes Compared to Patients With Standard Modifiable Risk Factors

Balamrit Singh Sokhal - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Myocardial infarction

N/A

Practical Adherence to AHA/ACC 2018 Guidelines Among Secondary Prevention Patients

Aleesha Kainat - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

N/A

The Relationship Between Anxiety, Cumulative Social Risk, and Adherence to Antihypertensive Medications

Onoriode Kesiena - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Anxiety

N/A

A Polygenic Risk Score Added to a QRISK2 Cardiovascular Risk Calculator Demonstrated Robust Clinical Acceptance in the Primary Care Setting

Ahmet Fuat - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Prevalence and Clinical Characteristics of Patients With Decompensated Heart Failure and Clonal Haematopoiesis of Indeterminate Potential

Leanne Mooney - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

N/A

Multi-Ancestry Genome-Wide Association Analysis in 1.9 Million Individuals Identifies 49 New Genetic Loci for Heart Failure and Related Subtypes

Albert Henry - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Myocardial infarction

N/A

Sex Differences in Healthcare Resource Utilization in Patients With Atrial Fibrillation Receiving Dronedarone versus Sotalol Following Ablation

Emily P Zeitler - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Arrhythmia

Dronedarone

Factors Influencing Timely Recognition and Treatment of Severe Hypertension in Pregnancy

Jay Parekh - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Hypertension

N/A

Copyright © 2026. QuantiNova All rights reserved